secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001193125-26-049953
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics forms JV Trimmune with WY Biotech; receives $3.5M upfront plus equity worth $3.5M
--------------------------------------------------------------------------------

- Exclusive worldwide license for HCW11-006 in vivo applications; option for Greater China rights to HCW9302.
- Upfront cash fee of $3.5M ($1.75M paid now, remainder due by March 6, 2026) plus co-founder equity valued at ~$3.5M.
- Eligible for development milestone payments, double-digit royalties, and share of future transaction proceeds.
- HCW Biologics retains royalty-free option to reclaim Americas rights after Phase 1; Phase 1 trial expected H1 2027.
- JV Trimmune backed by CITIC Medical Fund and TigerMed; expenses for Phase 1 in China paid by Trimmune.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000119312526049953/0001193125-26-049953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000119312526049953/hcwb-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-049953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer